Workflow
Luna(LUNA)
icon
Search documents
HALPER SADEH LLC ENCOURAGES LUNA INNOVATIONS INCORPORATED SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Prnewswire· 2025-12-05 19:16
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Luna Innovations Incorporated (OTCMKTS: LUNA) breached their fiduciary duties to shareholders.If you currently own Luna stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-ap ...
EDUARDO LUNA APPOINTED LEAD DIRECTOR OF VIZSLA SILVER
Prnewswire· 2025-09-17 12:00
Core Viewpoint - Vizsla Silver Corp. has appointed Mr. Eduardo Luna as Lead Director of the Board, recognizing his extensive experience in the mining industry and his contributions to the company's progress towards becoming a leading silver producer [2][4]. Company Leadership - Mr. Eduardo Luna, an independent director since November 15, 2023, has been appointed as Lead Director, bringing four decades of experience in the mining sector [2][3]. - Luna has previously held significant roles in companies such as Goldcorp and Wheaton River, and has been instrumental in developing major mines in Mexico, including the San Dimas Mine [2][3]. Incentive Compensation - The company has granted 1,550,000 performance-based restricted share units (PRSUs) to officers, employees, and consultants, which will vest over three years following the announcement of the Feasibility Study for the Panuco Project [4]. Panuco Project Overview - The Panuco silver-gold project is located in southern Sinaloa, Mexico, covering 7,189.5 hectares with over 86 kilometers of vein extent and existing infrastructure [5]. - The project contains intermediate to low sulfidation epithermal silver and gold deposits, primarily associated with volcanic activity [6]. Mineral Resource Estimate - As of January 6, 2025, the Panuco Project has an estimated in-situ combined measured and indicated mineral resource of 222.4 million ounces of silver equivalent (AgEq) and an inferred resource of 138.7 million ounces AgEq [7]. Economic Highlights - A Preliminary Economic Study completed in July 2024 indicates an annual production of 15.2 million ounces AgEq over an initial mine life of 10.6 years, with an after-tax NPV at 5% of US$1.1 billion, an IRR of 86%, and a payback period of 9 months at silver and gold prices of US$26/oz and US$1,975/oz respectively [7].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Luna Innovations Incorporated - LUNA
Prnewswire· 2025-02-04 20:55
Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Luna Innovations Incorporated and its officers or directors [1] Group 1: Company Developments - On January 6, 2025, Luna Innovations announced its inability to meet the March 27, 2025 deadline for filing delinquent reports with the SEC, leading to a suspension of trading in its securities on January 7, 2025, and subsequent delisting from Nasdaq [2] - Following the announcement, Luna Innovations' stock price experienced a significant decline during intraday trading on January 6, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [3]
Luna(LUNA) - 2024 Q4 - Annual Results
2025-01-27 15:26
[FORM 8-K Filing Information](index=1&type=section&id=FORM%208-K%20Filing%20Information) This section provides foundational information for the Form 8-K filing, including registrant details and filing date [Registrant and Filing Details](index=1&type=section&id=Registrant%20and%20Filing%20Details) This section provides the foundational information for the Form 8-K filing, including the registrant's identity, jurisdiction, contact details, and the date of the earliest reported event - The report is a Current Report on Form 8-K, filed by LUNA INNOVATIONS INCORPORATED[1](index=1&type=chunk)[2](index=2&type=chunk) - The date of the earliest event reported is January 27, 2025[2](index=2&type=chunk) - The registrant's telephone number is (540) 769-8400[3](index=3&type=chunk) [Securities Information](index=1&type=section&id=Securities%20Information) This part details the company's registered securities and confirms its status regarding emerging growth company provisions Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :--------------------------------------- | | Common Stock, $0.001 par value per share | LUNA | Nasdaq Stock Market, LLC | - The registrant is not an emerging growth company[6](index=6&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section details the preliminary financial results for the fiscal year ended December 31, 2024 [Preliminary Financial Results Announcement](index=2&type=section&id=Preliminary%20Financial%20Results%20Announcement) Luna Innovations Incorporated announced preliminary financial results for its fiscal year ended December 31, 2024, through a press release - On January 27, 2025, Luna Innovations Incorporated issued a press release providing preliminary financial results for the fiscal year ended December 31, 2024[7](index=7&type=chunk) - A copy of the press release is attached as Exhibit 99.1[7](index=7&type=chunk) [Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](index=2&type=section&id=Item%203.01%20Notice%20of%20Delisting%20or%20Failure%20to%20Satisfy%20a%20Continued%20Listing%20Rule%20or%20Standard%3B%20Transfer%20of%20Listing) This section outlines the company's plans for delisting from Nasdaq and deregistering from the SEC [Delisting from Nasdaq and SEC Deregistration Plan](index=2&type=section&id=Delisting%20from%20Nasdaq%20and%20SEC%20Deregistration%20Plan) Luna Innovations announced plans to accelerate the delisting of its common stock from Nasdaq and deregister from the SEC, citing eligibility due to having fewer than 300 record holders - The Company announced plans to accelerate the delisting of its common stock from The Nasdaq Stock Market LLC and deregister under Section 12(b), Section 12(g) and Section 15(d) of the Exchange Act[8](index=8&type=chunk) - The Company anticipates filing a Form 25 for delisting and deregistration around February 6, 2025, with effectiveness 10 days and 90 days, respectively, after filing[8](index=8&type=chunk) - Eligibility for deregistration and Form 15 filing is due to having fewer than **300 holders of record** of its common stock as of December 31, 2024, which immediately suspends reporting obligations under Section 13(a)[8](index=8&type=chunk) [Post-Deregistration Trading Market](index=2&type=section&id=Post-Deregistration%20Trading%20Market) Following deregistration, Luna Innovations anticipates its common stock will trade on the OTC Expert Market, though there is no guarantee that a trading market will be maintained - The Company anticipates its common stock will remain on the OTC Expert Market[9](index=9&type=chunk) - No guarantee can be made that a trading market in the Company's common stock in any over-the-counter market will be maintained[9](index=9&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) This section includes a standard cautionary statement regarding forward-looking statements, specifically addressing expectations about the delisting and deregistration process and associated risks, including those related to the OTC Expert Market - The report contains forward-looking statements regarding the delisting from Nasdaq and deregistration from the SEC[10](index=10&type=chunk) - Management cautions that these statements are predictions subject to known and unknown risks and uncertainties, which may cause actual results to differ materially[10](index=10&type=chunk) - Factors include risks associated with the OTC Expert Market and those detailed in the Company's Form 10-Q and subsequent SEC filings[10](index=10&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=3&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists all exhibits accompanying the Form 8-K filing, including press releases and interactive data files [Exhibits Filed](index=3&type=section&id=Exhibits%20Filed) This section lists the exhibits accompanying the Form 8-K filing, which include a press release and an interactive data file Exhibits | Exhibit | Description | | :------ | :---------- | | 99.1 | Press Release dated January 27, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Signatures](index=4&type=section&id=Signatures) This section confirms the official signing and submission of the Form 8-K report by an authorized corporate officer [Report Signatures](index=4&type=section&id=Report%20Signatures) The Form 8-K report was duly signed on behalf of Luna Innovations Incorporated by an authorized officer - The report was signed by Ryan Stewart, SVP, General Counsel and Corporate Secretary of Luna Innovations Incorporated[13](index=13&type=chunk) - The report was signed on January 27, 2025[13](index=13&type=chunk)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Luna Innovations Incorporated - LUNA
ACCESSWIRE Newsroom· 2025-01-16 23:30
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Luna Innovations Incorporated - LUNA ...
Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
GlobeNewswire News Room· 2024-11-15 21:05
– Investor & analyst webcast, including a key opinion leader panel, to be held Monday, November 18th at 7:30 a.m. EST REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, plans to host a webcast to report 52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data, and to provide key pivotal program design elements Monday, November ...
LUNA INNOVATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Luna Innovation, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2024-09-25 01:00
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Luna Innovation, Inc. (NASDAQ: LUNA) on behalf of long-term stockholders following a class action complaint that was filed against Luna Innovation on April 1, 2024 with a Class Period from August 11, 2023 to March 25, 2024. Our investigation concerns whether the board of directors of Luna Innovation have breached their fiduciary duties to th ...
NORWEGIAN CRUISE LINE® UNVEILS ITS NEXT CUTTING-EDGE VESSEL -THE ALL-NEW NORWEGIAN LUNA™
Prnewswire· 2024-09-18 18:37
- Open for Sale Today, the Sister Ship to Norwegian Aqua™, Will Debut in March 2026 with Seven-Day Caribbean Voyages from the Cruise Capital of the World – Miami - - Norwegian Luna™ will 'Shine Brighter' with Celestial Hull Art Inspired by the Reflection of Moonlight on the Sea by Celebrated Street Artist – ELLE - MIAMI, Sept. 18, 2024 /PRNewswire/ -- Norwegian Cruise Line® (NCL), the innovator in global cruise travel, today unveiled and opened for sale the next evolution of its Prima Plus Class, the all-ne ...
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
GlobeNewswire News Room· 2024-07-17 06:45
- Safety: 100% of 6E10 difluprednate-alone patients had no or minimal inflammation, and none received corticosteroids for treatment of inflammation beyond the scheduled prophylaxis - 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Patient Preference Survey: 88% of patients indicated a preference for Ixo-vec over their prior anti-VEGF injections, and 93% would opt to receive Ixo-vec in the othe ...
LUNA Stockholders: Robbins LLP is Investigating the Officers and Directors of Luna Innovations Incorporated; Contact the Firm for More Information
Newsfilter· 2024-06-28 22:41
Group 1 - Luna Innovations Incorporated is under investigation by Robbins LLP for potential violations of securities laws and breaches of fiduciary duties by its officers and directors related to financial reporting [2] - The company specializes in technology focused on fiber optics, with products aimed at the aerospace, automotive, and communications sectors [2] - Shareholders of Luna Innovations Incorporated who have incurred financial losses have legal options available to them [3] Group 2 - Robbins LLP has a history of successfully litigating securities class actions and has recovered over $1 billion for shareholders since its inception in 2002 [4]